| Literature DB >> 30271397 |
Hao Dong1, Xiaowei Peng2, Yufu Liu2,3, Tonglei Wu4, Xiaolei Wang5, Yanyan De6, Tao Han1, Lin Yuan1, Jiabo Ding2, Chuanbin Wang1, Qingmin Wu6.
Abstract
Brucella spp. are intracellular pathogens that infect a wide variety of mammals including humans, posing threats to the livestock industry and human health in developing countries. A number of genes associated with the intracellular trafficking and multiplication have so far been identified in Brucella spp. However, the sophisticated post-transcriptional regulation and coordination of gene expression that enable Brucella spp. to adapt to changes in environment and to evade host cell defenses are not fully understood. Bacteria small RNAs (sRNAs) play a significant role in post-transcriptional regulation, which has already been confirmed in a number of bacteria but the role of sRNAs in Brucella remains elusive. In this study, we identified several different sRNAs in Brucella spp., and found that over-expression of a sRNA, tentatively termed BASI74, led to alternation in virulence of Brucella in macrophage infection model. The expression level of BASI74 increased while Brucella abortus 2308 was grown in acidic media. In addition, BASI74 affected the growth ratio of the Brucella cells in minimal media and iron limiting medium. Using a two-plasmid reporter system, we identified four genes as the target of BASI74. One target gene, BABI1154, was predicted to encode a cytosine-N4-specific DNA methyltransferase, which protects cellular DNA from the restriction endonuclease in Brucella. These results show that BASI74 plays an important role in Brucella survival in macrophage infection model, speculatively by its connection with stress response or impact on restriction-modification system. Our study promotes the understanding of Brucella sRNAs, as well as the mechanism by which sRNAs use to influence Brucella physiology and pathogenesis.Entities:
Keywords: Brucella; intracellular survival; post-transcriptional regulation; sRNA; stress response; virulence
Year: 2018 PMID: 30271397 PMCID: PMC6146029 DOI: 10.3389/fmicb.2018.02173
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Verified sRNA in this work.
| sRNA Name | sRNA start | end | Length of sRNA (nt) |
|---|---|---|---|
| BAS I 365 | 24475 | 24577 | 102 |
| BAS I 371 | 29595 | 29988 | 393 |
| BAS I 387 | 47061 | 47307 | 246 |
| BAS I 22 | 100793 | 100872 | 79 |
| BAS I 23 | 100828 | 100944 | 116 |
| BAS I 262 | 128868 | 129114 | 246 |
| BAS I 35 | 254741 | 254855 | 114 |
| BAS I 62 | 521937 | 522023 | 86 |
| BAS I 74 | 713147 | 713233 | 86 |
| BAS I 84 | 815539 | 815617 | 78 |
| BAS I 244 | 1098391 | 1098472 | 81 |
| BAS I 245 | 1099846 | 1100145 | 299 |
| BAS I 122 | 1173218 | 1173318 | 100 |
| BAS I 130 | 1221129 | 1221226 | 97 |
| BAS I 133 | 1249641 | 1249811 | 170 |
| BAS I 137 | 1289949 | 1290101 | 152 |
| BAS I 151 | 1441442 | 1441521 | 79 |
| BAS I 273 | 1445660 | 1445799 | 139 |
| BAS I 9 | 1490038 | 1490143 | 105 |
| BAS I 283 | 1500367 | 1500491 | 124 |
| BAS I 176 | 1603445 | 1603565 | 120 |
| BAS I 304 | 1648877 | 1649137 | 260 |
| BAS I 306 | 1662860 | 1663033 | 173 |
| BAS I 193 | 1688162 | 1688286 | 124 |
| BAS I 214 | 1971684 | 1971765 | 81 |
| BAS I 344 | 2005699 | 2006063 | 364 |
| BAS I 345 | 2017052 | 2017142 | 90 |
| BAS I 218 | 2032657 | 2032746 | 89 |
| BAS I 221 | 2056362 | 2056509 | 147 |
| BAS I 228 | 2084505 | 2084582 | 77 |
| BAS II 152 | 873615 | 873740 | 125 |
| BAS II 36 | 295058 | 295164 | 106 |
| BAS II 47 | 433815 | 433936 | 121 |
| BAS II 149 | 75638 | 75764 | 126 |
| BAS II 37 | 309649 | 309775 | 126 |
| BAS II 99 | 1099166 | 1099368 | 202 |
| BAS II 39 | 325182 | 325397 | 215 |
| BAS II 133 | 508838 | 509001 | 163 |
| BAS II 5 | 580622 | 580840 | 218 |
| BAS II 73 | 824439 | 824525 | 86 |
| BAS II 150 | 824439 | 824613 | 174 |
| BAS II 74 | 824439 | 824637 | 198 |
| BAS II 117 | 381044 | 381193 | 149 |
Multiplication ability of sRNA over expression strains in J774A.1 macrophages.
| sRNA Name | 1 h CFU | Over-expression strain/WT(1 h) | 48 h CFU | Over-expression strain/WT(48 h) | sRNA Name | 1 h CFU | Over-expression strain/WT(1 h) | 48 h CFU | Over-expression strain/WT (48 h) |
|---|---|---|---|---|---|---|---|---|---|
| BAS I 74 | 1.98E + 03 | 33.51% | 9.17E + 03 | 0.61% | BAS I 306 | 8.42E + 02 | 14.23% | 4.98E + 05 | 33.40% |
| BAS I 22 | 9.67E + 02 | 16.34% | 4.05E + 05 | 27.14% | BAS I 344 | 8.66E + 03 | 146.32% | 8.61E + 05 | 57.70% |
| BAS I 23 | 8.33E + 02 | 14.08% | 2.45E + 05 | 16.42% | BAS I 345 | 8.42E + 02 | 14.23% | 2.28E + 05 | 15.30% |
| BAS I 35 | 1.28E + 03 | 21.55% | 1.23E + 05 | 8.27% | BAS I 365 | 2.24E + 03 | 37.89% | 4.16E + 05 | 27.87% |
| BAS I 62 | 2.71E + 03 | 45.77% | 2.62E + 05 | 17.54% | BAS I 371 | 9.33E + 02 | 15.77% | 5.83E + 05 | 39.04% |
| BAS I 9 | 8.33E+02 | 14.08% | 7.52E + 05 | 50.38% | BAS I 387 | 5.42E + 03 | 91.55% | 1.02E + 06 | 68.16% |
| BAS I 84 | 2.80E + 03 | 47.32% | 4.33E + 05 | 29.04% | BAS II 5 | 2.01E + 03 | 33.94% | 3.66E + 05 | 24.52% |
| BAS I 122 | 1.10E + 03 | 18.59% | 1.15E + 06 | 77.08% | BAS II 36 | 8.42E + 02 | 14.23% | 3.18E + 05 | 21.34% |
| BAS I 130 | 8.67E + 03 | 146.48% | 1.10E + 06 | 73.39% | BAS II 37 | 1.15E + 03 | 19.44% | 6.55E + 05 | 43.90% |
| BAS I 133 | 1.63E + 03 | 27.46% | 5.52E + 05 | 36.97% | BAS II 39 | 1.57E + 03 | 26.48% | 3.68E + 05 | 24.69% |
| BAS I 137 | 3.11E + 03 | 52.53% | 8.50E + 05 | 56.97% | BAS II 47 | 1.99E + 03 | 33.67% | 4.15E + 05 | 27.81% |
| BAS I 151 | 1.91E + 03 | 32.25% | 7.80E + 05 | 52.28% | BAS II 73 | 9.08E + 02 | 15.35% | 3.22E + 05 | 21.56% |
| BAS I 176 | 2.28E + 03 | 38.45% | 2.84E + 05 | 19.05% | BAS II 74 | 1.15E + 03 | 19.49% | 6.33E + 05 | 42.45% |
| BAS I 193 | 1.49E + 03 | 25.22% | 5.88E + 05 | 39.43% | BAS II 99 | 1.60E + 03 | 27.04% | 3.33E + 05 | 22.34% |
| BAS I 214 | 2.31E+03 | 39.01% | 5.47E + 05 | 36.64% | BAS II 117 | 5.42E + 03 | 91.55% | 6.23E + 05 | 41.78% |
| BAS I 218 | 1.79E + 03 | 30.29% | 5.58E + 05 | 37.42% | BAS II 133 | 3.27E + 03 | 55.21% | 9.51E + 05 | 63.73% |
| BAS I 221 | 8.33E + 03 | 140.83% | 1.25E + 06 | 83.44% | BAS II 149 | 1.50E + 03 | 25.35% | 4.96E + 05 | 33.23% |
| BAS I 228 | 1.81E + 03 | 30.56% | 1.00E + 06 | 67.02% | BAS II 152 | 2.90E + 03 | 49.01% | 8.02E + 05 | 53.73% |
| BAS I 244 | 5.50E + 03 | 92.95% | 9.47E + 05 | 63.45% | BAS II 150 | 1.50E + 03 | 25.35% | 4.96E + 05 | 33.23% |
| BAS I 245 | 1.03E + 03 | 17.46% | 8.27E + 05 | 55.41% | 2308-pBBR1 | 2.14E + 03 | 36.20% | 1.00E + 06 | 67.09% |
| BAS I 262 | 9.25E + 02 | 15.63% | 3.97E + 05 | 26.59% | 2308 | 5.92E + 03 | 100.00% | 1.49E + 06 | 100.00% |
| BAS I 273 | 8.42E + 02 | 14.23% | 3.95E + 05 | 26.47% | |||||
| BAS I 283 | 7.08E + 03 | 119.71% | 5.17E + 05 | 34.63% | |||||
| BAS I 304 | 1.28E + 03 | 21.68% | 4.19E + 05 | 28.09% |
Verification of the interaction between BASI74 and putative target sequences.
| Putative target genes | β- galactosidase activity (Miller units) | Fold change BASI74/vector | ||
|---|---|---|---|---|
| pUT18C | pUT18C-BASI74 | |||
| BAB1_0097 | 9.21 ± 2.23 | 11.61 ± 2.71 | 1.26 | 0.8093 |
| BAB1_0343 | 3.15 ± 1.21 | 2.01 ± 0.83 | 0.64 | 0.1253 |
| BAB1_0847 | 15.57 ± 2.77 | 23.65 ± 2.57 | 1.52 | <0.05 |
| BAB1_1154 | 14.99 ± 2.41 | 47.18 ± 1.935 | 3.15 | <0.001 |
| BAB1_1335 | 4.18 ± 0.32 | 1.36 ± 0.48 | 0.33 | <0.05 |
| BAB1_1361 | 5.48 ± 1.81 | 2.03 ± 1.64 | 0.37 | <0.05 |
The transcriptional levels of four verified target genes in 2308-BASI74 and ΔBASI74.
| Gene | Fold change | |
|---|---|---|
| 2308-BASI74 vs. 2308 | ΔBASI74 vs. 2308 | |
| BAB1_1361 | 4.52 | 1.32 |
| BAB1_1335 | 2.69 | 1.17 |
| BAB1_1154 | 7.89 | 0.93 |
| BAB1_0847 | 3.89 | 0.77 |